Feb 27, 2009 - OSI Pharmaceuticals, Inc. announced that the Company received notification from the U.S. PTO that an initial office action has been issued regarding OSI's application for a reissue of the Company's composition of matter patent for Tarceva (erlotinib), U.S. Patent No. 5747498.
The details can be read here.
No comments:
Post a Comment